Opioid Detection: Headwall Hyperspectral Imaging Technology

 

Headwall announced that its hyperspectral imaging technology is part of a proposal by Battelle chosen as a first-stage finalist for the Department of Homeland Security (DHS) Science and Technology (S&T) Directorate Opioid Detection Challenge.

The Automated Multimodal Opioid Detection system by Battelle uses Headwall hyperspectral imaging sensors, as well as dual-energy radiography and machine-learning algorithms, to non-invasively detect opioids in packages without disrupting the flow of mail.

“We thrive on working with companies like Battelle with a long track record of success on projects that save lives,” David Bannon, CEO of Headwall commented. “Our hyperspectral sensors offer a powerful combination of machine vision sensing, real-time processing capability, and a ruggedized design that already benefits thousands of customers around the world with instruments on the process line, on the farms, in the air, and even in space. Helping to reduce the human cost of addiction by automated interdiction has great social impact and means a great deal to us and our community.”

According to the White House, the abuse of opioids such as fentanyl has created an unprecedented public health crisis across the United States. In 2017, approximately 50,000 Americans died from opioid overdoses. International mail has been identified as a route for illicit opioids entering the United States, commonly transported in nearly pure, powdered form. Consequently, large-scale drug trafficking can occur via small packages sent in the mail.

As part of the comprehensive government effort to address the crisis, DHS S&T, U.S. Customs and Border Protection (CBP), the United States Postal Inspection Service (USPIS) and the Office of National Drug Control Policy (ONDCP), are seeking novel, automated, nonintrusive, user-friendly and well-developed designs for tools and technologies. The $1.55 million prize competition attracted 83 submissions from around the world.

The Battelle/Headwall system now moves on to a 14-week accelerator stage, during which a deployable prototype will be developed. Government and industry mentors will provide specialized support on topics such as the inspection process, trace detection, artificial intelligence, and user design. These tools would be deployed in international mail, express consignment facilities, and other environments across the country.

About Headwall

Headwall Photonics is a leading designer and manufacturer of spectral instrumentation for remote sensing, advanced machine vision, medical/biotech, and government/defense markets. With a worldwide base of end-user and OEM customers, Headwall enjoys a market leadership position through the design and manufacture of spectral solutions that are customized for application-specific performance. The Company is based in Massachusetts where it has two locations (Bolton and Fitchburg). European operations (Headwall BVBA) are located near Brussels, Belgium.

About Battelle

Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Headquartered in Columbus, Ohio since its founding in 1929, Battelle serves the national security, health and life sciences, and energy and environmental industries. For more information, visit www.battelle.org.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Headwall Photonics, Inc.. (2019, September 11). Opioid Detection: Headwall Hyperspectral Imaging Technology. AZoOptics. Retrieved on September 19, 2019 from https://www.azooptics.com/News.aspx?newsID=24535.

  • MLA

    Headwall Photonics, Inc.. "Opioid Detection: Headwall Hyperspectral Imaging Technology". AZoOptics. 19 September 2019. <https://www.azooptics.com/News.aspx?newsID=24535>.

  • Chicago

    Headwall Photonics, Inc.. "Opioid Detection: Headwall Hyperspectral Imaging Technology". AZoOptics. https://www.azooptics.com/News.aspx?newsID=24535. (accessed September 19, 2019).

  • Harvard

    Headwall Photonics, Inc.. 2019. Opioid Detection: Headwall Hyperspectral Imaging Technology. AZoOptics, viewed 19 September 2019, https://www.azooptics.com/News.aspx?newsID=24535.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit